What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone produced in the gut after eating. Originally developed for type 2 diabetes management, GLP-1 medications have become the most clinically significant advancement in medical weight loss in decades — producing average weight loss of 15–22% of body weight in clinical trials, results that were previously only achievable with bariatric surgery.
The two most widely used GLP-1 medications for weight management are:
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss) — a GLP-1 receptor agonist administered weekly via subcutaneous injection
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — a dual GLP-1 and GIP receptor agonist; the addition of GIP activity produces greater weight loss than semaglutide alone
How GLP-1 Medications Work
GLP-1 receptor agonists produce weight loss through multiple overlapping mechanisms, which is why their effects exceed what can be achieved through willpower or caloric restriction alone:
- Appetite suppression via the brain — GLP-1 receptors in the hypothalamus and brainstem directly reduce hunger drive and the reward value of food. Patients commonly report simply not thinking about food the way they used to.
- Delayed gastric emptying — Food moves more slowly from the stomach to the small intestine, extending the sensation of fullness after smaller portions
- Improved insulin sensitivity — GLP-1 medications stimulate glucose-dependent insulin secretion and reduce glucagon, improving blood sugar control and reducing the hyperinsulinemia that drives fat storage
- Reduced food noise — Clinical observations and patient reports consistently describe a reduction in intrusive thoughts about food and compulsive eating behaviors, suggesting central nervous system effects beyond simple appetite suppression
- GIP co-agonism (tirzepatide only) — Glucose-dependent insulinotropic polypeptide (GIP) receptor activation enhances insulin secretion, improves fat metabolism, and appears to amplify the weight loss effects of GLP-1 agonism alone
Clinical Trial Results: What the Data Shows
The clinical evidence for GLP-1 medications is among the strongest ever published for a non-surgical weight loss intervention:
| Medication | Trial | Duration | Average Weight Loss | % Achieving 15%+ Weight Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | STEP 1 (NEJM, 2021) | 68 weeks | 14.9% body weight | 50% of participants |
| Tirzepatide 15mg | SURMOUNT-1 (NEJM, 2022) | 72 weeks | 20.9% body weight | 57% of participants |
| Semaglutide 2.4mg | SELECT trial (NEJM, 2023) | 3.3 years | ~10% sustained loss | 20% reduction in cardiovascular events |
The SELECT trial (2023) was particularly significant: it demonstrated that semaglutide reduced the risk of major adverse cardiovascular events — including heart attack, stroke, and cardiovascular death — by 20% in overweight and obese patients without diabetes. This moved GLP-1 medications from weight loss drugs to cardiovascular risk-reduction agents in clinical practice guidelines.
Who Qualifies for GLP-1 Medications?
FDA-approved indications for weight management GLP-1 medications:
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
In practice, many functional medicine and obesity medicine clinicians also consider GLP-1 medications for patients with:
- Documented insulin resistance or metabolic syndrome, even at lower BMI
- Non-alcoholic fatty liver disease (NAFLD)
- Polycystic ovarian syndrome (PCOS) with metabolic features
- Weight loss resistance despite optimized diet, exercise, and hormone management
GLP-1 medications are contraindicated in: Personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), active pancreatitis, pregnancy, and severe gastrointestinal disease.
Semaglutide vs. Tirzepatide: Which Is Better for Weight Loss?
| Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Average weight loss | ~15% of body weight | ~21% of body weight |
| Injection frequency | Weekly | Weekly |
| FDA approval (weight) | Wegovy (2021) | Zepbound (2023) |
| Starting dose | 0.25mg/week, titrated to 2.4mg | 2.5mg/week, titrated to 15mg |
| Availability | Improving after shortage; compounded available | Improving; compounded available |
| Cost (brand) | ~$1,300/month without insurance | ~$1,060/month without insurance |
A 2023 head-to-head analysis published in JAMA Internal Medicine comparing matched cohorts on semaglutide vs. tirzepatide found tirzepatide users were significantly more likely to achieve 10%, 15%, and 20% weight loss thresholds at all timepoints measured. For most patients without contraindications, tirzepatide currently produces greater weight loss outcomes.
Side Effects and How to Manage Them
GLP-1 medications are generally well-tolerated when started at low doses and titrated slowly. The most common side effects are gastrointestinal:
- Nausea — Most common, especially during dose escalation. Typically improves after the first 2–4 weeks at each dose level. Managed by slow titration, eating smaller portions, and avoiding high-fat meals.
- Constipation — Common due to slowed gastric motility. Addressed with increased water intake, fiber, and magnesium supplementation.
- Vomiting and diarrhea — Less common; usually associated with too-rapid dose escalation or dietary triggers.
- Fatigue — Occasionally reported, particularly in the first weeks. Often improves as the body adjusts.
- Injection site reactions — Mild redness or discomfort at the injection site; usually resolves quickly.
Rare but serious risks: Acute pancreatitis, acute gallbladder disease (gallstones), and a theoretical (not definitively established in humans) risk of thyroid C-cell tumors based on rodent studies. Patients with prior pancreatitis or significant gallbladder history require individual risk assessment.
The Muscle Loss Problem — and How to Address It
One of the most significant clinical concerns with GLP-1 medication weight loss is muscle loss. Studies show that 25–40% of weight lost on GLP-1 medications may be lean mass rather than fat mass — a ratio significantly worse than what is achieved with diet and exercise alone (typically 15–25% lean mass loss).
Preserving muscle during GLP-1 treatment is critical because muscle mass determines resting metabolic rate, physical function, longevity, and insulin sensitivity. A functional medicine approach addresses this directly:
- Protein intake: Target 1.0–1.6g of protein per pound of lean body mass daily — higher than standard dietary guidelines, but necessary to stimulate muscle protein synthesis on a caloric deficit
- Resistance training: 2–3 sessions per week of progressive resistance exercise is the most effective intervention to preserve lean mass during caloric restriction
- Hormone optimization: Low testosterone (in both sexes) accelerates muscle loss during caloric restriction. Optimizing testosterone and thyroid function before or during GLP-1 treatment significantly improves body composition outcomes
- Creatine supplementation: 3–5g/day of creatine monohydrate has strong evidence for preserving lean mass during caloric restriction
Weight Regain After Stopping GLP-1 Medications
The STEP 1 Extension trial (2022) found that patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. This is not a failure of willpower — it reflects that GLP-1 medications address a physiological dysregulation that returns when the medication is discontinued.
This has important implications for treatment planning:
- GLP-1 medications are most effective as long-term treatments for most patients with obesity, not short courses
- Using GLP-1 medications as a bridge to sustainable lifestyle change — while simultaneously addressing root causes of weight loss resistance (hormones, insulin resistance, gut health, sleep) — gives patients the best chance of maintaining results if they eventually discontinue
- Some patients transition to lower maintenance doses rather than fully stopping
GLP-1 Medications Within a Functional Medicine Framework
At Pro-Fit High Performance Medicine, GLP-1 medications are integrated into a comprehensive weight loss program — not prescribed in isolation. Our approach addresses the full metabolic picture:
- Root cause evaluation: Identifying and addressing insulin resistance, thyroid dysfunction, adrenal dysregulation, sex hormone imbalances, and sleep disorders that contribute to weight loss resistance
- Hormone optimization: Ensuring testosterone, thyroid, and other hormones are at optimal levels to support fat loss and muscle preservation during GLP-1 treatment
- Nutrition protocol: High-protein dietary structure to offset GLP-1-related appetite suppression and prevent lean mass loss
- Exercise programming: Resistance training protocols timed to GLP-1 treatment
- Metabolic monitoring: Regular labs to track insulin sensitivity, body composition, and metabolic health markers throughout treatment
GLP-1 Weight Loss in Birmingham, Alabama
Pro-Fit High Performance Medicine offers medical weight loss programs including GLP-1 medications (semaglutide and tirzepatide) from our Vestavia Hills clinic, serving Birmingham, Mountain Brook, Homewood, Hoover, Pelham, and surrounding areas. Telehealth weight loss consultations are available across Alabama, Texas, Georgia, Florida, South Carolina, and Kentucky.
Our medical weight loss program includes comprehensive metabolic lab testing, hormone evaluation, individualized GLP-1 protocol design, nutritional guidance, and ongoing monitoring — all within our broader functional medicine framework.
Frequently Asked Questions About GLP-1 Medications
How much weight can I lose on semaglutide or tirzepatide?
Clinical trials show average weight loss of approximately 15% of body weight with semaglutide (Wegovy) at 68 weeks, and approximately 21% with tirzepatide (Zepbound) at 72 weeks. Individual results vary significantly based on starting weight, adherence, diet, exercise, and underlying metabolic health. Patients who also optimize hormones and address insulin resistance tend to achieve better outcomes.
Do I have to take GLP-1 medications forever?
For most patients with obesity, GLP-1 medications are most effective as long-term treatments. The STEP 1 Extension trial showed that approximately two-thirds of lost weight is regained within one year of stopping. However, using GLP-1 medications while actively improving metabolic health, body composition, and lifestyle habits gives patients the best chance of maintaining results if they eventually taper or discontinue. Some patients transition to lower maintenance doses.
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain semaglutide, but they are approved for different indications and use different dosing regimens. Ozempic (doses up to 2mg) is FDA-approved for type 2 diabetes management. Wegovy (doses up to 2.4mg) is FDA-approved specifically for chronic weight management. The higher maximum dose in Wegovy is associated with greater weight loss than the doses used for diabetes management.
Will I lose muscle on GLP-1 medications?
GLP-1 medications carry a real risk of lean mass loss alongside fat loss, with some studies showing 25–40% of weight lost may be muscle. This makes protein intake and resistance exercise critical components of any GLP-1 program. Optimizing testosterone and thyroid function before and during treatment further reduces muscle loss. At Pro-Fit HPM, body composition monitoring and a structured muscle-preservation protocol are standard parts of our GLP-1 programs.
Is tirzepatide better than semaglutide for weight loss?
Head-to-head data from a 2023 JAMA Internal Medicine analysis shows tirzepatide produces greater weight loss than semaglutide at all dose levels and timepoints measured. Average weight loss with tirzepatide was approximately 21% of body weight vs. 15% with semaglutide. Tirzepatide’s dual GLP-1/GIP mechanism is the primary driver of its greater efficacy. Individual patient factors, tolerability, and cost also influence which medication is most appropriate.